These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 33423844)

  • 1. Current and emerging strategies for management of myelodysplastic syndromes.
    Saygin C; Carraway HE
    Blood Rev; 2021 Jul; 48():100791. PubMed ID: 33423844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?
    Bewersdorf JP; Zeidan AM
    Expert Rev Hematol; 2020 Oct; 13(10):1131-1142. PubMed ID: 32876498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
    Garcia-Manero G; Chien KS; Montalban-Bravo G
    Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
    Bewersdorf JP; Zeidan AM
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplastic syndromes current treatment algorithm 2018.
    Steensma DP
    Blood Cancer J; 2018 May; 8(5):47. PubMed ID: 29795386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes.
    Hochman MJ; DeZern AE
    Clin Lymphoma Myeloma Leuk; 2024 Sep; 24(9):573-582. PubMed ID: 38594129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategies in low and high-risk MDS: What does the future have to offer?
    Scalzulli E; Pepe S; Colafigli G; Breccia M
    Blood Rev; 2021 Jan; 45():100689. PubMed ID: 32253020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raising the bar for lower-risk myelodysplastic syndromes.
    Venugopal S; Sekeres MA
    Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in myelodysplastic syndromes: promising novel agents and combination strategies.
    Madanat YF; Xie Z; Zeidan AM
    Expert Rev Hematol; 2023 Jan; 16(1):51-63. PubMed ID: 36620919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.
    DeZern AE; Malcovati L; Ebert BL
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():400-410. PubMed ID: 31099654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
    Pophali P; Desai SR; Shastri A
    Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
    Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
    Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genetic and molecular pathogenesis of myelodysplastic syndromes.
    Shallis RM; Ahmad R; Zeidan AM
    Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.
    Lee P; Yim R; Yung Y; Chu HT; Yip PK; Gill H
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches.
    Brunner AM; Steensma DP
    Clin Adv Hematol Oncol; 2018 Jan; 16(1):56-66. PubMed ID: 29741506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How we manage adults with myelodysplastic syndrome.
    Fenaux P; Platzbecker U; Ades L
    Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
    Lucero J; Al-Harbi S; Yee KWL
    Curr Oncol; 2023 Jun; 30(7):6177-6196. PubMed ID: 37504319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.